Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience

Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience

Acute promyelocytic leukemia is a variant of acute myeloid leukemia characterised by t(15;17) and PML/RAR alfa fusion gene. The invention of the molecular pathogenesis has led to entitle all-trans retinoic acid (ATRA) as the primary focused remedy for acute leukemia. It’s often related to anthracycline-based chemotherapy with excessive response charges, however potential long-term sequelae together with therapy-related malignancies have been noticed.
Arsenic trioxide (ATO) was added to obviate these issues and investigational trials aimed to a brand new technique with the incorporation of arsenic trioxide (ATO) into preliminary remedy as an alternative of chemotherapy in chosen sufferers. ATRA plus ATO with out chemotherapy was the primary try to deal with low and intermediate-risk sufferers with APL. Our examine goals to explain a monocentric cohort of sufferers with newly recognized APL successfully handled with ATO plus ATRA underlying its efficacy along with the excessive grade of tolerability of this affiliation.
From January 2009 to December 2019 23 APL sufferers have been recognized and handled with ATO plus ATRA routine: 14 males and 9 females sufferers with a median age of 45 years (vary 18-72), for almost all intermediate threat (15 sufferers, 65%). The remedy was properly tolerated and all sufferers achieved molecular remission after a median time of three months (vary 1-6 months). All sufferers proceeded to consolidation section as outpatients, they maintained full molecular response at a median time of 44 months (vary 15-127) apart from 1 affected person.
All however one affected person are alive and in response at a median follow-up of 48 months (vary 9-141) with out late results. ATO plus ATRA routine exhibits benefits compared to chemotherapy; actually it allowed to deal with sufferers during which chemotherapy may even not be relevant and it didn’t present secondary hematological ailments. The affiliation of ATO to ATRA as chemo-free routine enabled to deal with APL even with out chemotherapy.

Investigation of the ameliorative results of baicalin in opposition to arsenic trioxide-induced cardiac toxicity in mice

Baicalin (BA), a form of flavonoids compound, comes from Scutellaria baicalensis Georgi (a form of perennial herb) and has useful results on the cardiovascular system by means of anti-oxidant, anti-inflammation, and anti-apoptosis actions. Nevertheless, the therapeutic results and latent mechanisms of BA on arsenic trioxide (ATO)-induced cardiac toxicity has not been reported. The current analysis was carried out to discover the results and mechanisms of BA on ATO-induced coronary heart toxicity.
Male Kunming mice have been handled with ATO (7.5 mg/kg) to induce cardiac toxicity. After the mice obtained ATO, BA (50 and 100 mg/kg) was administered for estimating its cardioprotective results. Statistical information demonstrated that BA remedy alleviated electrocardiogram abnormalities and pathological harm attributable to ATO.
BA may additionally result in restoration of CK and LDH actions to regular vary and trigger a lower in MDA ranges and ROS technology, augmentation of SOD, CAT, and GSH actions. We additionally discovered that BA prompted a discount within the expression of proinflammatory cytokines, akin to TNF-α and IL-6. Furthermore, BA attenuated ATO-induced apoptosis by selling the expression of Bcl-2 and suppressing the expression of Bax and caspase-3. TUNEL take a look at consequence demonstrated BA prompted obstacle of ATO-induced apoptosis.
Moreover, BA remedy suppressed the excessive expression of TLR4, NF-κB and P-NF-κB attributable to ATO. In conclusion, these outcomes point out that BA might alleviate ATO-induced cardiac toxicity by restraining oxidative stress, apoptosis, and irritation, and its mechanism can be related to the inhibition of the TLR4/NF-κB signaling pathway.

Comparative Analysis of Mineral Trioxide Mixture Obturation Utilizing 4 Totally different Methods-A Laboratory Research

This examine aimed to check the density of mineral trioxide combination (MTA) as a root canal filling materials within the apical 5 mm of synthetic root canals. Forty clear acrylic blocks with 30-degree curved canals have been instrumented and allotted into 4 compaction method teams (n = 10): Lawaty (hand recordsdata); gutta-percha (GP) factors; auger (nickel-titanium rotary recordsdata in reverse mode); and plugger method. Crammed canals have been weighed after setting the MTA to calculate distinction in mass.
Two postoperative radiographs in contrast radiopacity by measuring luminance variations at 0.5 mm, 1 mm, 2 mm, Three mm, four mm, and 5 mm from the basis apex. Obturation time was measured utilizing a digital chronometer. The importance stage was set to p < 0.05. The plugger group had a decrease mass. Relative luminance was considerably greater for the Lawaty group than the plugger group in any respect examined apical ranges.
The relative luminance of the auger and GP teams have been considerably greater than the plugger group at depths between 0.5 mm and a couple of mm. Relative luminance was highest for the Lawaty method in any respect depths between 0.5 mm and four mm. The Lawaty method group was related to elevated obturation time in contrast with pluggers. Compacting MTA in curved canals with the Lawaty method has the best mass and radiopacity however requires extra time.
 Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience

Arsenic trioxide encapsulated liposomes prepared via copper acetate gradient loading method and its antitumor efficiency

In this study, arsenic trioxide (ATO) was encapsulated in liposomes via copper acetate (Cu(OAc)2) gradients and high entrapment efficiency of over 80% was obtained. The average particle size and the zeta-potential of the liposomes were detected to be 115.1 ± 29.1 nm and -21.97 ± 0.6 mV, respectively.
The TEM images showed rod-like precipitates in the inner aqueous phase, which was supposed be due to the formation of insoluble ATO-Cu complex. The in vitro drug release of ATO-Cu liposomes exhibited a sustained release over 72 h, and the release rates decreased with the increase of the pH of release media. Pharmacokinetic and tissue distribution studies of ATO liposomes showed significantly reduced plasma clearance rate, increased AUC0-12 h and T1/2, and improved tumor distribution of As compared to iv administration of ATO solution.
The anti-tumor effect of ATO loaded liposomes to S180 tumor-bearing mice was significantly improved with a tumor inhibition rate of 61.2%, meanwhile the toxicity of encapsulated ATO was greatly decreased.

Molybdenum trioxide 99.5%_x000D__x000D_

M31150 100G
EUR 227.4

Molybdenum

23316-12 25G
EUR 23.1

Molybdenum

M361000 10g
EUR 65
Description: 7439-98-7

Molybdenum trichloride 99.5%

M31145 1G
EUR 184.87

Molybdenum trisulfide dihydrate

M31160 5G
EUR 805.61

Antimony trioxide, Hi-AR™

GRM6604-100G 1 unit
EUR 10.5
Description: Antimony trioxide, Hi-AR™

Antimony trioxide, Hi-AR™

GRM6604-500G 1 unit
EUR 50.46
Description: Antimony trioxide, Hi-AR™

Molybdenum Dioxide

M30990 100G
EUR 200.55

Molybdenum disulfide

581228 100.0g
EUR 240

Molybdenum disulfide

T19986-10mg 10mg Ask for price
Description: Molybdenum disulfide

Molybdenum disulfide

T19986-1g 1g Ask for price
Description: Molybdenum disulfide

Molybdenum disulfide

T19986-1mg 1mg Ask for price
Description: Molybdenum disulfide

Molybdenum disulfide

T19986-50mg 50mg Ask for price
Description: Molybdenum disulfide

Molybdenum disulfide

T19986-5mg 5mg Ask for price
Description: Molybdenum disulfide

Molybdenum disulphide

RM6087-100G 1 unit
EUR 33.08
Description: Molybdenum disulphide

Molybdenum disulphide

RM6087-500G 1 unit
EUR 148.52
Description: Molybdenum disulphide

Molybdenum(Ⅵ) Oxide

23322-22 25G
EUR 14.35

Molybdenum(Ⅵ) Oxide

23322-35 500G
EUR 193.55

Molybdenum powder 99.95%

M30900 25G
EUR 190.7

Molybdenum boride, 99%

GX2434-50 50
EUR 451.4

Molybdenum boride, 99+%

GX5267-10 10
EUR 122.1

Molybdenum boride, 99+%

GX5267-50 50
EUR 301.3

Molybdenum boride, 98+%

GX5774-100 100
EUR 228.1

Molybdenum boride, 98+%

GX5774-25 25
EUR 111.5

Molybdenum carbide 99.8%

M30950 5G
EUR 67.9

Molybdenum Foil0.05mm, 99.9+%

GX5354-100 100
EUR 205.4

Molybdenum Foil0.05mm, 99.9+%

GX5354-150 150
EUR 337.3

Molybdenum carbonyl 98%

M30960 5G
EUR 208.03

Molybdenum diboride 97%

M30980 1G
EUR 92.6

Molybdenum silicide 99.5%

M31125 100G
EUR 540.33

Molybdenum(V) Chloride

M489000 10g
EUR 138
Description: 10241-05-1

Molybdenum silicide, 99.5%

GX2864-100 100
EUR 146.2

Molybdenum silicide, 99.5%

GX2864-250 250
EUR 268.8

Molybdenum phthalocyanine

M31100 1G
EUR 403.04

Chromium trioxide, Hi-AR™/ACS

GRM1357-500G 1 unit
EUR 14.82
Description: Chromium trioxide, Hi-AR™/ACS

Molybdenum disulfide 92%

M31020 100G
EUR 136.2

Molybdenum metal powder

GRM3558-25G 1 unit
EUR 69.38
Description: Molybdenum metal powder

Molybdenum(VI) oxide, 99.9%

GX8007-1 1
EUR 355.8

Molybdenum(VI) oxide, 99.9%

GX8007-100 100
EUR 99.7

Molybdenum(VI) oxide, 99.9%

GX8007-100G 100 g
EUR 156

Molybdenum(VI) oxide, 99.9%

GX8007-1KG 1 kg
EUR 466.8

Molybdenum(VI) oxide, 99.9%

GX8007-250 250
EUR 151.8

Molybdenum(VI) oxide, 99.9%

GX8007-250G 250 g
EUR 219.6

Molybdenum Foil 0.5mm, 99.95%

GX9163-100 100
EUR 231.3

Molybdenum Foil 1.0mm, 99.9+%

GX9760-100 100
EUR 309.6

Molybdenum Foil 1.0mm, 99.9+%

GX9760-150 150
EUR 313

Molybdenum Foil 0.2mm, 99.95%

GX1246-100 100
EUR 164.5

Molybdenum Foil 0.3mm, 99.95%

GX1962-100 100
EUR 203.6

Molybdenum Foil 0.1mm, 99.95%

GX2552-100 100
EUR 132.6

Molybdenum(VI) oxide, 99.0%

GX6266-250 250
EUR 119.1

Molybdenum(VI) oxide, 99.0%

GX6266-500 500
EUR 192.2

Molybdenum(IV) oxide, 99+%

GX0932-100 100
EUR 208.6

Molybdenum(IV) oxide, 99+%

GX0932-25 25
EUR 93.4

Molybdenum disilicide 99.5%

M31010 50G
EUR 321.6

Molybdenum Foil 0.25mm, 99.9+%

GX8943-100 100
EUR 120.5

Molybdenum Foil 0.25mm, 99.9+%

GX8943-150 150
EUR 182.5

Molybdenum Foil 0.25mm, 99.9+%

GX8943-50 50
EUR 98

Molybdenum Sheet 2mm, 99.9+%

GX9338-100 100
EUR 264

Molybdenum Sheet 1.5mm, 99.9+%

GX9615-100 100
EUR 215.1

Molybdenum Foil 0.025mm, 99.9+%

GX9911-100 100
EUR 177.5

Molybdenum Foil 0.025mm, 99.9+%

GX9911-150 150
EUR 220.1

Molybdenum Foil 0.025mm, 99.9+%

GX9911-50 50
EUR 104

Molybdenum Sheet 2.5mm, 99.9+%

GX3862-100 100
EUR 301.3

Molybdenum Foil 0.15mm, 99.95%

GX4416-100 100
EUR 140.2

Molybdenum Sheet 3mm, 99.9+%

GX6521-100 100
EUR 485.6

Molybdenum(II) carbide, 99.5+%

GX1923-100 100
EUR 129.6

Molybdenum(II) carbide, 99.5+%

GX1923-250 250
EUR 255.7

Molybdenum(IV) sulfide, 98+%

GX2871-1 1
EUR 241.2

Molybdenum(IV) sulfide, 98+%

GX2871-250 250
EUR 116.1

Molybdenum(IV) sulfide, 98+%

GX2871-500 500
EUR 146.2

Molybdenum hexafluoride 99%

M31040 50G
EUR 3926.85

Molybdenum Standard Solution

37521-24 100ML
EUR 21

Molybdenum cofactor sulfurase

AP84973 1mg
EUR 2640

Molybdenum cofactor sulfurase

AP85269 1mg
EUR 2640

Molybdenum cofactor sulfurase

AP85366 1mg
EUR 2640

ICP Std Molybdenum 1000ug/mL in H2O - 1L

PMO2C1L 1L
EUR 693.27

ICP Std Molybdenum 10000ug/mL in H2O - 250ML

RPMO4B7 250ML
EUR 265.85

ICP Std Molybdenum 1000ug/mL in 1% HCl - 100ML

PMO2A11 100ML
EUR 151.29

Molybdenum Rod 1 mm diameter, 99.95%

GX7974-1 1
EUR 105.5

Molybdenum Rod 2.0 mm diameter, 99.9+%

GX8666-1 1
EUR 164.5

Molybdenum Rod 2.0 mm diameter, 99.9+%

GX8666-500 500
EUR 102.4

Molybdenum Rod 10 mm diameter, 99.95%

GX8980-100 100
EUR 179.3

Molybdenum Rod 10 mm diameter, 99.95%

GX8980-250 250
EUR 332.3

Molybdenum Rod 1.5 mm diameter, 99.95%

GX9336-1 1
EUR 135.6

Molybdenum Rod 30 mm diameter, 99.9+%

GX9467-100 100
EUR 536.1

Molybdenum Rod 5.0 mm diameter, 99.95%

GX1673-100 100
EUR 114.5

Molybdenum Rod 5.0 mm diameter, 99.95%

GX1673-250 250
EUR 160.5

Molybdenum Rod 5.0 mm diameter, 99.95%

GX1673-500 500
EUR 269.6

Molybdenum Rod 20 mm diameter, 99.9+%

GX2933-100 100
EUR 303.1

Molybdenum Rod 20 mm diameter, 99.9+%

GX2933-500 500
EUR 1165.9

Molybdenum Rod 2.5 mm diameter, 99.9+%

GX3152-500 500
EUR 105.5

Molybdenum Rod 8.0 mm diameter, 99.9+%

GX3370-250 250
EUR 241.2

Molybdenum Rod 6.0 mm diameter, 99.9+%

GX4022-250 250
EUR 167.9

Molybdenum Rod 4.0 mm diameter, 99.9+%

GX5235-250 250
EUR 120.5

Molybdenum Rod 4.0 mm diameter, 99.9+%

GX5235-500 500
EUR 163

Molybdenum Rod 3.0 mm diameter, 99.9+%

GX6474-500 500
EUR 107

Molybdenum Rod 12 mm diameter, 99.9+%

GX0906-100 100
EUR 210.1

Molybdenum Wire 0.3 mm diameter, 99.95%

GX7025-100 100
EUR 228.1

Molybdenum Wire 0.3 mm diameter, 99.95%

GX7025-25 25
EUR 111.5

Molybdenum Wire 0.25 mm diameter, 99.95%

GX7146-100 100
EUR 184.1

Molybdenum Wire 0.25 mm diameter, 99.95%

GX7146-25 25
EUR 96.4

Molybdenum Wire 0.7 mm diameter, 99.95%

GX7237-10 10
EUR 105.5

Molybdenum Wire 0.7 mm diameter, 99.95%

GX7237-25 25
EUR 177.5

Molybdenum Wire 0.1 mm diameter, 99.95%

GX7396-100 100
EUR 125.1

Molybdenum Wire 0.1 mm diameter, 99.95%

GX7396-50 50
EUR 90.4

Molybdenum Wire 0.5 mm diameter, 99.95%

GX3073-100 100
EUR 382.9

Molybdenum Wire 0.5 mm diameter, 99.95%

GX3073-25 25
EUR 147.6

Molybdenum Powder, 2-5 micron, 99.95+%

GX4223-100 100
EUR 99.4

Molybdenum Powder, 2-5 micron, 99.95+%

GX4223-500 500
EUR 277.1

Molybdenum Wire 1.0 mm diameter, 99.95%

GX4703-25 25
EUR 290

Molybdenum Wire 1.0 mm diameter, 99.95%

GX4703-5 5
EUR 119.1

Molybdenum Wire 2.0 mm diameter, 99.95%

GX0175-1 1
EUR 126.5

Molybdenum Wire 2.0 mm diameter, 99.95%

GX0175-5 5
EUR 314.4

Molybdenum Wire 1.5 mm diameter, 99.95%

GX0574-1 1
EUR 99.4

Molybdenum Wire 1.5 mm diameter, 99.95%

GX0574-5 5
EUR 224.9

ICP Std Molybdenum 1000ug/mL in 2% NH4OH - 250ML

PMO2B7 250ML
EUR 240.3

ICP Std Molybdenum 1000ug/mL in 2% NH4OH - 500ML

PMO2C7 500ML
EUR 434.76

ICP Std Molybdenum 10000ug/mL in 2% NH4OH - 100ML

PMO4A7 100ML
EUR 259.98

ICP Std Molybdenum 10000ug/mL in 3.5% NH4OH - 500ML

PMO4B4-500ML 500ML
EUR 1038.44

Molybdenum Pellets 6 x 12 mm, 99.9+%

GX2699-100 100
EUR 198.7

Molybdenum Pellets 6 x 12 mm, 99.9+%

GX2699-25 25
EUR 99.4

Molybdenum Oxytetrachloride 97% _x000D_

M31060 10G
EUR 277.73

Molybdenum Powder max. 100 micron, 99.9%

GX3538-100 100
EUR 123.5

Molybdenum Powder max. 100 micron, 99.9%

GX3538-500 500
EUR 303.1

ICP Std Molybdenum 100ug/mL in 2% NH4OH - 100ML

PMO1A7 100ML
EUR 265.85

ICP Std Molybdenum 100ug/mL in 2% NH4OH - 500ML

PMO1C3 500ML
EUR 409.8

molybdenum cofactor sulfurase Antibody

E300911 200ul
EUR 275
Description: Available in various conjugation types.

Molybdenum(IV) disulfide Nanopowder, 99 %

GX4987-10 10
EUR 311.3

Molybdenum(IV) disulfide Nanopowder, 99 %

GX4987-25 25
EUR 593.2

AAS Molybdenum Std 1000ppm in H2O - 500ML

AAMOH 500ML
EUR 120.15

AAS Molybdenum Std 10000ppm in H2O - 500ML

AAMOM 500ML
EUR 380.7

Molybdenum Foil 0.1 mm, plane, shiny, 99.95%

GX4593-100 100
EUR 180.9

ICP Std Molybdenum 1000ug/mL in 2-5% HNO3 tr. HF - 100ML

PMO2A10 100ML
EUR 277.6

Molybdenum Cofactor Synthesis 2 Protein

20-abx263321
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 2 µg

Molybdenum Cofactor Synthesis 2 Protein

abx263321-10mg 10 mg
EUR 325

Molybdenum Cofactor Synthesis 2 Protein

abx263321-25mg 25 mg
EUR 1600

Molybdenum Cofactor Synthesis 2 Protein

abx263321-5mg 5 mg
EUR 225

Arsenic trioxide

A35645 500G
EUR 159

ICP Standard Molybdenum H2O 1000ug/ml - 100ML

PMO2A7 100ML
EUR 148.5

Chromium trioxide

GRM1057-1KG 1 unit
EUR 21.58
Description: Chromium trioxide

Chromium trioxide

GRM1057-500G 1 unit
EUR 12.03
Description: Chromium trioxide

Vanadium trioxide

V00590 25G
EUR 217.95

Molybdenum Cofactor Sulfurase (MOCOS) Antibody

abx235263-100ug 100 ug
EUR 577.2

Molybdenum Cofactor Sulfurase (MOCOS) Antibody

20-abx113870
  • Ask for price
  • Ask for price
  • 150 ul
  • 50 ul

Molybdenum Cofactor Sulfurase (MOCOS) Antibody

abx235263-100g 100 µg
EUR 350

Molybdenum Cofactor Sulfurase (MOCOS) Antibody

abx113870-100l 100 µl
EUR 612.5
In conclusion, ATO can be effectively encapsulated into liposomes by remote loading method via Cu(OAc)2 gradients; the co-administration of ATO and Cu(II) via liposomal formulation may find wide applications in the treatment of various tumors.

Leave a Reply

Your email address will not be published. Required fields are marked *